The stock reaction will likely hinge on how investors weigh the massive goodwill impairment against the underlying operational growth. The positive 2026 guidance suggests management is confident in the business's trajectory post-impairment. Traders should focus on the adjusted EPS and organic growth metrics as better indicators of fundamental health.
Price Chart
Executive Summary
Enovis reported full-year 2025 revenue growth of 7% (6% organically), driven by strong performance in Reconstructive (10% reported growth). However, results were marred by a $1.05 billion non-cash goodwill impairment charge, leading to a significant net loss. The company provided 2026 guidance for 4-6% organic revenue growth and adjusted EPS of $3.52-$3.73, signaling confidence in its recovery.
Key Financial Metrics
Key Facts
- Full-year 2025 revenue was $2.248 billion, a 7% increase from 2024.
- Reconstructive segment sales grew 10% YoY, while Prevention & Recovery grew 4%.
- A $1.05 billion goodwill impairment charge resulted in a full-year net loss of $1.182 billion.
- Adjusted EPS for 2025 was $3.30, down from $2.84 in 2024.
- 2026 guidance calls for revenue of $2.31-$2.37 billion (4-6% organic growth) and adjusted EPS of $3.52-$3.73.
Financial Impact
The $1.05 billion goodwill impairment charge is a massive one-time accounting loss that does not affect cash flow but severely impacts GAAP net income. The core business remains profitable on an adjusted basis (adjusted EBITDA of $403 million).
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Reconstructive | $1.1B | +10.0% |
| Prevention & Recovery | $1.1B | +4.0% |
Risk Factors
- The goodwill impairment indicates a significant write-down of asset value, which could signal deeper underlying issues or overpayment in past acquisitions.
- The Prevention & Recovery segment showed weak growth (4%), which could be a concern if it continues.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001420800-26-000008 |
| Document: cfx-20260226.htm | 0001420800-26-000008 |
| Document: 0001420800-26-000008-index-headers.html | 0001420800-26-000008 |
| Document: 0001420800-26-000008-index.html | 0001420800-26-000008 |
| Document: 0001420800-26-000008.txt | 0001420800-26-000008 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | Institutional Cluster | $20.81 $21.59 | ▼ −3.75% | ▼ −4.93% | $21.54 (−3.51%) |
Sep 8, 2026 6w ago | Insider Cluster | $19.03 $18.41 | ▼ −3.26% | ▼ −2.66% | $21.54 (+13.19%) |
Sep 4, 2026 7w ago | Insider Cluster | $19.98 $19.03 | ▼ −4.75% | ▼ −4.29% | $21.54 (+7.81%) |
Sep 1, 2026 8w ago | 8-K | $20.53 $20.20 | ▼ −1.61% | ▼ −2.05% | $21.54 (+4.92%) |
Jul 17, 2026 14w ago | Press Release | $27.07 $26.84 | ▼ −0.85% | ▼ −0.69% | $21.54 (−20.43%) |
May 7, 2026 24w ago | 8-K | $27.25 $26.52 | ▼ −2.68% | ▼ −3.51% | $21.54 (−20.95%) |
May 7, 2026 24w ago | Press Release | $27.25 $26.52 | ▼ −2.68% | ▼ −3.51% | $21.54 (−20.95%) |
Apr 10, 2026 28w ago | Press Release | $24.42 $24.86 | ▲ +1.80% | ▲ +0.83% | $21.54 (−11.79%) |
Feb 26, 2026 34w ago | 8-K | $25.42 $25.47 | ▲ +0.20% | ▲ +0.65% | $21.54 (−15.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers